View Older Stories

Mar 9, 2026 07:46AM Truist on Head of CBER at FDA Exit: 'we anticipate a positive stock reaction for IRON CAPT RGNX QURE'

Mar 9, 2026 07:39AM Mizuho's Jared Holz: 'We still like the sector, despite some recent setbacks like QURE and others'

Mar 9, 2026 07:38AM Stifel: 'Prasad is Out, QURE is on the Map, and Rare Disease Has Political Tailwinds'

Mar 9, 2026 07:11AM Wells Fargo Upgrades uniQure BV (QURE) to Overweight

Mar 9, 2026 05:34AM RBC Capital Upgrades uniQure BV (QURE) to Outperform

Mar 3, 2026 06:31AM TD Cowen Reiterates Buy Rating on uniQure BV (QURE)

Mar 3, 2026 04:44AM Wells Fargo Downgrades uniQure BV (QURE) to Equal Weight

Mar 3, 2026 02:16AM Mizuho Downgrades uniQure BV (QURE) to Neutral

Mar 2, 2026 04:07PM uniQure BV (QURE) PT Lowered to $35 at Leerink Partners

Mar 2, 2026 11:33AM RBC Capital Downgrades uniQure BV (QURE) to Sector Perform, Lowers PT to $11

Mar 2, 2026 11:23AM uniQure BV (QURE) PT Lowered to $14 at Stifel on FDA uncertainty

Mar 2, 2026 11:02AM Cantor Fitzgerald Downgrades uniQure BV (QURE) to Neutral following FDA recommendation

Mar 2, 2026 07:57AM Stifel Reiterates Buy Rating on uniQure BV (QURE)

Mar 2, 2026 07:02AM uniQure faces FDA hurdle for Huntington's disease gene therapy

Feb 26, 2026 02:28PM RBC Capita on uniQure BV (QURE): 'The Commissioner's comments are clearly disappointing'

Feb 26, 2026 11:53AM Stifel: 'We can see why QURE shares are lower on CNBC comments from FDA'

Feb 26, 2026 09:48AM UniQure stock tumbles on FDA comments about gene therapy trial

Feb 24, 2026 09:12AM Wolfe Research Starts uniQure BV (QURE) at Peerperform

Feb 6, 2026 11:10AM Options with increasing option implied volatility: MSTU XXRP ETHU QURE MSTZ BITX

Feb 6, 2026 07:06AM uniQure reports sustained enzyme activity in Fabry disease gene therapy trial

Feb 2, 2026 03:12PM uniQure (QURE) call put ratio 5.8 calls to 1 put with a focus on March 15 puts and April 70 calls

Jan 23, 2026 06:48AM H.C. Wainwright Reiterates Buy Rating on uniQure BV (QURE)

Jan 14, 2026 07:04AM uniQure (QURE) Reiterated at Overweight by Cantor Fitzgerald: FDA Feedback Key

Jan 12, 2026 05:11AM uniQure (QURE) spreader of 6K contracts of April 30 and 40 calls

Jan 9, 2026 07:05AM uniQure schedules FDA meeting on Huntington's therapy approval

Dec 9, 2025 04:29AM uniQure BV (QURE) PT Lowered to $33 at Mizuho

Dec 4, 2025 07:06AM uniQure receives FDA feedback on Huntington's disease gene therapy

Nov 11, 2025 04:32AM William Blair Reiterates Market Perform Rating on uniQure BV (QURE)

Nov 10, 2025 02:54PM uniQure BV (QURE) PT Lowered to $50 at Stifel

Nov 10, 2025 01:18PM uniQure BV (QURE) PT Lowered to $60 at Leerink Partners

Nov 10, 2025 07:09AM uniQure (QURE) Misses Q3 EPS by 47c

Nov 5, 2025 08:16AM Raymond James on Biohaven Pharmaceutical Holding (BHVN): 'Meaningful Value Remains', 'Sticking with it'

Nov 4, 2025 08:44AM uniQure BV (QURE) PT Lowered at RBC Capital After a 'Disappointing Regulatory Update'

Nov 4, 2025 06:43AM uniQure BV (QURE) PT Lowered to $70 at H.C. Wainwright, maintained as Top Pick

Nov 4, 2025 04:17AM William Blair Downgrades uniQure BV (QURE) to Market Perform

Nov 3, 2025 10:00AM Truist: 'QURE Update Minimal Read-Through To PTCT & WVE, In Our View'

Nov 3, 2025 09:38AM uniQure (QURE) halted on volatility

Nov 3, 2025 09:24AM Raymond James on Biohaven (BHVN) Amid News Shock: 'QURE Sympathy Move Seems Misplaced'

Nov 3, 2025 07:38AM Biohaven Pharma (BHVN) Weakness May Be Tied to uniQure (QURE) Setback in Huntington's Disease

Nov 3, 2025 07:06AM UniQure faces FDA setback on Huntington's disease gene therapy

Oct 6, 2025 06:47AM uniQure BV (QURE) PT Raised to $110 at H.C. Wainwright

Sep 25, 2025 07:07AM uniQure BV (QURE) PT Raised to $95 at Guggenheim

Sep 25, 2025 07:02AM uniQure BV (QURE) PT Raised to $80 at Cantor Fitzgerald

Sep 25, 2025 07:02AM uniQure BV (QURE) PT Raised to $80 at Cantor Fitzgerald

Sep 25, 2025 06:59AM Bristol Myers Squibb expands direct-to-patient drug sales program

Sep 25, 2025 06:59AM Mizuho Upgrades uniQure BV (QURE) to Outperform

Sep 25, 2025 05:12AM uniQure BV (QURE) PT Raised to $65 at Wells Fargo

Sep 25, 2025 04:20AM uniQure BV (QURE) PT Raised to $60 at Mizuho

Sep 25, 2025 04:02AM Goldman Sachs Reiterates Neutral Rating on uniQure BV (QURE)

Sep 24, 2025 01:08PM uniQure BV (QURE) PT Raised to $68 at Leerink, 'topline results from the pivotal Phase 1/2 study of AMT-130 in Huntington's disease (HD) as a definitive win'

View Older Stories